65694 Federal Register / Vol. 83, No. 245 / Friday, December 21, 2018 / Notices 

federal employees during a competition 

if the facilities and employees are made 

equitably available to all individuals 

and entities participating in the 

competition; 

(12) Must provide a statement 

agreeing to indemnify the federal 

government against third party claims 

for damages arising from or related to 

competition activities; 

(13) Must provide a statement 

agreeing to assume all risks and waive 

claims against the Federal Government 

and its related entities, except in the 

case of willful misconduct, for any 

injury, death, damage, or loss of 

property, revenue, or profits, whether 

direct, indirect, or consequential, arising 

from participation in this prize contest, 

whether the injury, death, damage, or 

loss arises through negligence or 

otherwise. 

(14) HHS has hereby waived the 

requirement for participants to obtain 

liability insurance in a specified amount 

for this competition. Participants are 

advised to consult with appropriate 

advisors to determine what amounts of 

insurance may be necessary for their 

own liability protection. 

(15) Shall not be currently on the 

Excluded Parties List (https://

www.epls.gov). 

Additional Requirements 

Entrants shall not use the OWH or 

HHS logos or official seals in their 

submissions, and must not claim 

endorsement. 

HHS reserves the right to cancel, 

suspend, and/or modify the Shape of 

Health competition, or any part of it, for 

any reason, at HHS’ sole discretion. 

Payment of the Prize: Prizes awarded 

under this competition will be paid by 

electronic funds transfer and may be 

subject to Federal income taxes. HHS 

will comply with the Internal Revenue 

Service withholding and reporting 

requirements, where applicable. 

Intellectual Property (IP) 

• Each entrant retains full ownership 

and title in and to their submission. 

Entrants expressly reserve all 

intellectual property rights not 

expressly granted under this publication 

notice. 

• By participating in the competition, 

each entrant hereby irrevocably grants 

to HHS a limited, non-exclusive, 

royalty-free, worldwide license and 

right to reproduce, publically perform, 

publically display, and use the 

submission for internal HHS business 

and to the extent necessary to 

administer the competition, and to 

publically perform and publically 

display the submission, including, 

without limitation, for advertising and 

promotional purposes relating to the 

competition. 

• Record Retention and FOIA: All 

materials submitted to HHS as part of a 

submission become HHS records and 

cannot be returned. Any confidential 

commercial information contained in a 

submission should be designated at the 

time of submission. Participants will be 

notified of any Freedom of Information 

Act requests for their submissions in 

accordance with 45 CFR 5.65. 

SUPPLEMENTARY INFORMATION: 

Information on obesity prevention and 

control in women and girls can be found 

at: 

https://www.cdc.gov/obesity/ 

resources/strategies-guidelines.html 

https://www.womenshealth.gov/a-ztopics/overweight-obesity-and-weightloss 

https://www.girlshealth.gov/nutrition/ 

healthyweight/ 

Details on the Shape of Health 

competition may be found at 

challenge.gov. 

FOR FURTHER INFORMATION CONTACT: Ann 

Abercrombie at Ann.Abercrombie@

hhs.gov. 

Dated: November 28, 2018. 

Brett Giroir, 

ADM, Assistant Secretary for Health. 

[FR Doc. 2018–27653 Filed 12–20–18; 8:45 am] 

BILLING CODE 4150–33–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: ‘‘Multifunctional RNA 

Nanoparticles and Methods of Uses’’ 

and ‘‘RNA/DNA Hybrid Nanoparticles 

Modified With Single Stranded RNA 

Toeholds and Uses Thereof’’ 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patent Applications listed in the 

Supplementary Information section of 

this notice to Sixfold Biosciences Inc., 

(‘‘Sixfold’’) of Walnut, California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 7, 2019 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Jasmine Yang, Sr. Licensing 

and Patenting Manager, NCI Technology 

Transfer Center, 9609 Medical Center 

Drive, RM 1E530 MSC 9702, Bethesda, 

MD 20892–9702 (for business mail), 

Rockville, MD 20850–9702 Telephone: 

(240)–276–5530; Facsimile: (240)-276– 

5504 Email: jasmine.yang@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

A. Multifunctional RNA Nanoparticles 

and Methods of Uses 

1. U.S. Provisional Patent Application 

(Application No. 61/878,758) filed 

September 17, 2013, HHS Reference 

No.: E–765–2013–0–US–01 

2. PCT Application (Application No. 

PCT/US2014/056007) filed 

September 17, 2014, HHS Reference 

No.: E–765–2013–0–US–02 

3. European Patent Application 

(Application No. 14780963.6) filed 

September 17, 2014, HHS Reference 

No.: E–765–2013–0–EP–03 

4. Australian Patent Application 

(Application No. 2014321443) filed 

September 17, 2014, HHS Reference 

No.: E–765–2013–0–AU–04 

5. Canadian Patent Application 

(Application No. 2,924,509) filed 

September 17, 2014, HHS Reference 

No.: E–765–2013–0–CA–05 

6. Japanese. Patent Application 

(Application No. 2016–543964) 

filed September 17, 2014, HHS 

Reference No.: E–765–2013–0–JP– 

05 

7. US Patent Application (Application 

No. 15/022,530) filed March 16, 

2016, HHS Reference No.: E–765– 

2013–0–US–07 

B. RNA/DNA Hybrid Nanoparticles 

Modified with Single Stranded RNA 

Toeholds and Uses Thereof 

1. U.S. Provisional Patent Application 

(Application No. 62/294,848) filed 

February 12, 2016, HHS Reference 

No.: E–078–2016–0–US–01 

2. PCT Application (Application No. 

PCT/US2017/017661) filed 

February 13, 2017, HHS Reference 

No.: E–078–2016–0–US–02 

3. US Patent Application (Application 

No. 16/076,878) filed August 9, 

2018, HHS Reference No.: E–078– 

2016–0–US–03 

4. European Patent Application 

(Application No. 17706653.7) filed 

September 12, 2018, HHS Reference 

No.: E–078–2016–0–EP–04 

The patent rights in these inventions 

have been assigned and/or exclusively 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 245 / Friday, December 21, 2018 / Notices 65695 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be where patent 

applications are filed and the field of 

use may be limited to ‘‘Multifunctional 

RNA nanoparticle functionalized by 

RNA toeholds as a drug delivery agent 

carrying gene therapeutic or geneediting cargo and/or aptamers’’. 

Additional licensable fields of use are 

available (e.g. functionalized with 

proteins or imaging agent). 

The technologies disclose RNA and 

RNA/DNA (‘‘R/DNA’’) nanoparticles in 

the form of a hexameric ring that have 

arms attached off the sides of the ring 

in which the arms could be siRNAs, 

RNA aptamers, fluorescent dyes, 

imaging agents and/or proteins in 

various combinations and use of singlestranded RNA toeholds of lengths of 12 

nucleotides or less contained in nucleic 

acid-based nanoparticles, such as the 

nanoring, which trigger the association 

of these nanoparticles and activates 

multiple functionalities such as gene 

silencing and/or cell-specific targeting. 

This notice is made in accordance with 

35 U.S.C. 209 and 37 CFR part 404. The 

prospective exclusive license will be 

royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated; December 11, 2018. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2018–27671 Filed 12–20–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke, Interagency Pain 

Research Coordinating Committee Call 

for Committee Membership 

Nominations 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) (Department) 

has created the Interagency Pain 

Research Coordinating Committee 

(IPRCC) and is seeking nominations for 

this committee. 

DATES: Nominations are due by 5 p.m. 

on January 25, 2019. 

ADDRESSES: Nominations must be 

submitted through the webform on the 

IPRCC website: https://iprcc.nih.gov/ 

About/Membership-AgencyRepresentation/Nomination-Form. 

FOR FURTHER INFORMATION CONTACT: 

Linda Porter at 301–451–4460 or email 

at porterl@ninds.nih.gov. 

SUPPLEMENTARY INFORMATION: As 

specified in Public Law 111–148 

(‘‘Patient Protection and Affordable Care 

Act’’) and amended in H.R. 6, (‘‘Support 

for Patients and Communities Act’’) the 

Committee will: 

(A) Develop a summary of advances 

in pain care research supported or 

conducted by the Federal agencies 

relevant to the diagnosis, prevention, 

treatment, and management of pain and 

diseases and disorders associated with 

pain, including information on best 

practices for the utilization of nonpharmacologic treatments, nonaddictive medical products, and other 

drugs or devices approved or cleared by 

the Food and Drug Administration; 

(B) identify critical gaps in basic and 

clinical research on 

(i) the symptoms and causes of pain, 

including the identification of relevant 

biomarkers and screening models and 

the epidemiology of acute and chronic 

pain; 

(ii) the diagnosis, prevention, 

treatment, and management of acute and 

chronic pain, including with respect to 

non-pharmacologic treatments, nonaddictive medical products, and other 

drugs or devices approved or cleared by 

the Food and Drug Administration; and 

(iii) risk factors for, and early warning 

signs of, substance use disorders in 

populations with acute and chronic 

pain; 

(C) make recommendations to the 

Director of NIH 

(i) to ensure that the activities of the 

National Institutes of Health and other 

Federal agencies are free of unnecessary 

duplication of effort; 

(ii) on how best to disseminate 

information on pain care and 

epidemiological data related to acute 

and chronic pain; and 

(iii) on how to expand partnerships 

between public entities and private 

entities to expand collaborative, crosscutting research. 

Membership on the committee will 

include six (6) non-Federal members 

from among scientists, physicians, and 

other health professionals and six (6) 

non-Federal members of the general 

public who are representatives of 

leading research, advocacy, and service 

organizations for individuals with painrelated conditions. Members will serve 

overlapping three year terms. It is 

anticipated that the committee will meet 

at least once a year. 

The Department strives to ensure that 

the membership of HHS Federal 

advisory committees is fairly balanced 

in terms of points of view represented 

and the committee’s function. Every 

effort is made to ensure that the views 

of diverse ethnic and racial groups and 

people with disabilities are represented 

on HHS Federal advisory committees, 

and the Department therefore, 

encourages nominations of qualified 

candidates from these groups. The 

Department also encourages geographic 

diversity in the composition of the 

Committee. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. 

The Department is soliciting 

nominations for 5 non-federal members 

from among scientists, physicians, and 

other health professionals and for 3 nonfederal members of the general public 

who represent a leading research, 

advocacy, or service organization for 

people with pain-related conditions. 

These candidates will be considered to 

fill positions opened through 

completion of current member terms. 

Nominations are due by 5 p.m. on 

January 25, 2019, using the IPRCC 

nomination webform: https://

iprcc.nih.gov/About/MembershipAgency-Representation/NominationForm. 

Dated: December 11, 2018. 

Walter J. Koroshetz, 

Director, National Institute of Neurological 

Disorders and Stroke, National Institutes of 

Health. 

[FR Doc. 2018–27737 Filed 12–20–18; 8:45 am] 

BILLING CODE 4140–01–P 


amozie on DSK3GDR082PROD with NOTICES1